Azathioprine Metabolites in Erythrocytes and DNA for Therapy Monitoring in Very Early Onset Inflammatory Bowel Disease Pediatric Patients
Open Access
- 5 June 2025
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 8 (7) , 2009-2017
Abstract
Azathioprine is used for inflammatory bowel disease (IBD) therapy. Patients under 6 years of age (very early onset, VEO-IBD) showed distinctive clinical characteristics, such as increased activity of thiopurine-methyltransferase (TPMT), a crucial enzyme for thiopurine metabolism. TPMT and PACSIN2 polymorphisms were associated with azathioprine efficacy. This study investigated the role of age in thiopurine active metabolites and disease activity. Also, the effects of age, TPMT and PACSIN2 polymorphisms on azathioprine metabolites and disease activity were evaluated. Erythrocytes thioguanine nucleotides (TGN) were measured by HPLC, and leukocytes incorporated deoxythioguanosine (DNA-TG) byLC-MS/MS in 12 VEO-IBD patients (median age 4.13 ± 0.98, 7 females, 6 Crohn’s disease (CD)), 11 IBD children (median age 9.36 ± 1.52, 8 females, 1 CD ), and 73 IBD adolescents (median age 14.92 ± 1.81, 33 females, 37 CD). VEO-IBD subjects required a higher azathioprine dose (p-value = 0.048) and showed a lower DNA-TG/azathioprine dose ratio (p-value = 0.049) and TGN/azathioprine dose ratio (p-value = 0.013). DNA-TG was positively correlated with TGN (p-value = 4.15 × 10–5) and disease score (p-value = 1.54 × 10–4). TPMT rs1142345 (76 wild type, 10 heterozygous) was associated with increased concentrations of DNA-TG and TGN (p-value = 0.024 and 0.00038, respectively), whereas PACSIN2 rs2413739 (37 wild types, 34 heterozygous, 16 homozygous variants) was associated with the disease score (p-value = 0.04). Together, these data confirmed that VEO-IBD patients show enhanced azathioprine metabolism, which can be accurately reflected by both TGN and DNA-TG levels, highlighting their ability to be good biomarkers of azathioprine metabolism.Keywords
Funding Information
- Ministero della Salute (RC 21/17)
- Ministero della Salute (RC 23/23)
This publication has 33 references indexed in Scilit:
- Innovating Thiopurine Therapeutic Drug Monitoring: A Systematic Review and Meta-Analysis on DNA-Thioguanine Nucleotides (DNA-TG) as an Inclusive Biomarker in Thiopurine TherapyClinical Pharmacokinetics, 2024
- DNA‐Thioguanine Nucleotides as a Marker for Thiopurine Induced Late Leukopenia after Dose Optimizing by NUDT15 C415T in Chinese Patients with IBDClinical Pharmacology & Therapeutics, 2022
- Rac1/pSTAT3 expression: A pharmacodynamic marker panel as a first step toward optimization of thiopurine therapy in inflammatory bowel disease patientsCytometry Part A, 2021
- Increased DNA-incorporated thiopurine metabolite as a possible mechanism for leukocytopenia through cell apoptosis in inflammatory bowel disease patients with NUDT15 mutationJournal of Gastroenterology, 2021
- Effective long-term solution to therapeutic remission in Inflammatory Bowel Disease: Role of AzathioprineBiomedicine & Pharmacotherapy, 2018
- Epigenetics in Drug ResponseClinical Pharmacology & Therapeutics, 2016
- Epigenetic regulation of drug metabolism and transportActa Pharmaceutica Sinica B, 2015
- Pediatric modification of the Montreal classification for inflammatory bowel diseaseInflammatory Bowel Diseases, 2011
- Increased dosing requirements for 6-mercaptopurine and azathioprine in inflammatory bowel disease patients six years and youngerInflammatory Bowel Diseases, 2008
- High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sampleJournal of Chromatography B: Biomedical Sciences and Applications, 1992